Femasys completes the first in-office commercial procedure with the fda-cleared femaseed infertility solution

-- paving the way forward for the broader commercial availability of femaseed, an accessible, safe, and cost effective alternative to ivf -- -- ongoing uncertainty following recent alabama supreme court ruling creates continued anticipation with top-line pivotal data expected to be announced during q1 2024 --
FEMY Ratings Summary
FEMY Quant Ranking